Prolonged fasting in humans results in diminished plasma choline concentrations but does not cause liver dysfunction |
| |
Authors: | L Savendahl MH Mar LE Underwood SH Zeisel |
| |
Affiliation: | The Lipid Research Laboratory, Rambam Medical Center, Technion Faculty of Medicine and the Rappaport Institute for Research in the Medical Sciences, Haifa, Israel. skeidar@rambam.health.gov.il |
| |
Abstract: | The potential antiatherogenic actions of the angiotensin II receptor antagonist, losartan were investigated in apolipoprotein (apo) E deficient mice, an animal model with severe hypercholesterolemia and extensive atherosclerosis. In these animals accelerated atherosclerosis is associated with increased lipid peroxidation which may play a crucial role in the build up of the atherosclerotic lesions. Administration of losartan (25mg/kg/d) to the apo E deficient mice for a 3-month period increased the plasma renin activity 3.5-fold compared to the placebo group. Losartan increased the resistance of LDL to CuSO4-induced oxidative modification as shown by a significant reduction in the LDL content of malondialdehyde by 55% compared to placebo, as well as by the prolongation of the lag time required for LDL oxidation, from 60 min in the placebo-treated mice to more than 140 min in the losartan-treated mice. Losartan reduced significantly the mean atherosclerotic lesion area by 80% compared to the placebo group. We conclude that losartan inhibits LDL lipid peroxidation in the apo E deficient mice and this effect may have an important role in the attenuation of the accelerated atherosclerosis. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|